Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

7th Eurasian Hematology Oncology Summit
Avatar

2020 Update on High-Risk MDS: Does Aza Improve OS/ORR? How to Minimize Toxicity? Is Cytarabine Still the SoC? Are Novel Agents Promising?

By 7th Eurasian Hematology Oncology Summit FEATURING Moshe Mittelman
By 7th Eurasian Hematology Oncology Summit FEATURING Moshe Mittelman
56 views
December 11, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
MDS and MPN
15:05
7th Eurasian Hematology Oncology Summit

2020 Updates on MDS: Is Deferasirox Beneficial for EFS? Can We Achie…

Feat. G. Garcia-Manero
18:36
7th Eurasian Hematology Oncology Summit

2020 Update on High-Risk MDS: Does Aza Improve OS/ORR? How to Minimi…

Feat. M. Mittelman
11:32
7th Eurasian Hematology Oncology Summit

2020 Updates on MDS: Role of Prognostic Models, Cytogenetics, IPSS, …

Feat. G. Garcia-Manero
26:20
7th Eurasian Hematology Oncology Summit

2020 Update on MPNs: What Is the Risk Adapted Management in PV? Is R…

Feat. T. Mughal